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1. Introduction
It is the believe of many that tissue engineering (or as some
scientists prefer – regenerative medicine) is and will
increasingly be the focus of biomaterials research, justified
by a very significant and well-known clinical need for the
establishment of alternative therapies for the treatment of
tissue loss or end-stage organ failure, as the transplantation
of tissues or organs in these patients is often limited by
donor scarcity and is highly associated to the risk of rejec-
tion and disease transfer. In this sense, tissue engineering
will lead to a great impact on health care providing in the
coming decades.
This expected evolution would also create the need for
the education of new scientists that are ‘‘hybrid’’ and can
perform multidisciplinary research, combining materials
and biotechnology. Nevertheless, even the basics of tissue
engineering are not clear for many researchers working on
the general field of biomaterials and biomedical engineer-
ing. Conventional biomaterials have been very useful in the
past, and have improved the life quality of many patients.
Good examples are many different prosthesis, such as for
instances the knee and hip joints. However it is easy to
recognize that there are still no materials available that
can adequately replace several functional tissues, such
as bones, cartilage, or large bone segments, not to speak
on complex organs. Just as an example, in the world market
for bone grafts the so-called synthetic biomaterials
represent only 10%, while autografts still account
for around 50%. Therefore, despite the enormous benefits
the contemporary technology has brought, the outer
limits have been reached and new breakthroughs can only
be expected from a novel hybrid technology that will
reduce the shortcomings of the current material technology.
Such a combined, biology driven approach is referred to as
‘‘tissue engineering’’, by which biological tissues are
engineered through combining material technology and
biotechnology.
Tissue engineering typically involves the culture of
living human cells usually in polymeric (ceramic) scaffold
materials, ex vivo, and subsequently allowing them to
develop into a three dimensional tissue.
Substantial gains are expected to be obtained both from a
medical and economic standpoint as a result of this emerg-
ing technology. It is expected that, in the near future, tissue
engineering can take advantage of the recent breakthroughs
in the fields of stem cell research, genomics and materials
technology.
Tissue engineering involves several steps, that go from (i)
the selection, isolation, and culturing of primary (progeni-
tor or stem from different origins) cells, inducing their
differentiation to specific phenotypes, (ii) to the way they
are cultured (not pre-cultured and just seeded and immedi-
ately implanted, or cultured in static conditions or in an all
range of different specifically designed bio-reactors), (iii)
to the design of adequate scaffolds, including the selection
of adequate materials and routes to process them, the
respective porosity, interconnectivity, surface characteris-
tics, hydrophilicity, etc., and (iv) to the use of adequate
animal models that will allow to test the efficacy of different
tissue engineering approaches and the potential of different
constructs (distinct combinations of scaffolds/cells/in vitro
culturing conditions). Finally, all the related ethical consi-
derations, especially when considering the use of stem cells
(and potentially embryonic stem cells) and animal studies,
as well as the need for proper standards must be taken into
account, and unfortunately tend to differ from country to
country.
This introductory essay will very briefly present the state-
of-the-art on topics such as: cells for tissue engineering
(stem cells, isolation, characterization, etc.), culturing con-
ditions (static, media, bioreactors, etc.), scaffolds (design,
processing, choice of materials, etc.) and needed animal
models to test the developed tissue engineering strategies
and respective constructs.
The Special Topic on Tissue Engineering, that Macro-
molecular Bioscience invited me to organize as a Guest
Editor, comprises a selection of papers that touch several
relevant and emerging topics on tissue engineering, pro-
viding the reader with a feeling on what is the present status
of the field.
2. Scaffolds for Tissue Engineering
Tissue engineering offers the possibility to help in the
regeneration of tissues damaged by disease or trauma and in
some cases to create new tissues and replace failing or
malfunctioning organs.[1–7] This is typically done through
the use of degradable biomaterials to either induce
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surrounding tissue and cell ingrowth or to serve as
temporary scaffolds for transplanted cells to attach, grow,
and maintain differentiated functions.[3–5,7–17] In any case,
the role of the biomaterial is temporary, but rather crucial to
the success of the strategy. Therefore, the selection of a
scaffold material is both a critical and difficult choice.
There are many biocompatible materials available
among metals, ceramics and polymers, but the criteria of
biodegradability and non-brittle nature (ideally with tissue
matching mechanical properties) excludes the use of all
metals and most ceramics as scaffolds materials[3,18] and
gives preference to biodegradable polymers for most of the
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applications within the tissue engineering and regenerative
medicine field.
Consequently, the first aspect of the scaffold design to be
considered is related to the selection of the biodegradable
polymer that will be used for its design and production.
Traditionally, in spite of the wide range of biodegradable
polymers available, there is a strong tendency to choose
those that have history of regulatory approval. This leads to
the use of materials, which were primarily developed for
other applications (the so-called ‘‘from-the shelf’’ materi-
als), instead of letting the application guide the choice of the
material.[19] In fact poly(lactic acid) and poly(glycolic acid)
are still the gold standard,[11,20–24] although some other
groups such as ourselves[25–34] defend the use of other types
of biodegradable polymers. This conservative behavior of
the research community has created additional difficul-
ties for the development of new materials with improved
properties, specifically tailored for tissue engineering
applications.
The definition of the most adequate scaffold design and
the correspondent required properties, is mainly deter-
mined by the tissue engineering approach selected for the
regeneration of a specific tissue, as the scaffold must be
able to induce the desired tissue response.[35,36] Although
three-dimensional porous structures have been recognized
as the most appropriate design to sustain cell adhesion and
proliferation, several specific applications in tissue engi-
neering may take advantage of other design formats or
combination of different materials designs.[19] In fact, as the
demand for new and more sophisticated scaffolds develops,
materials are being designed that have a more active role in
guiding tissue development. Instead of merely holding cells
in place, these matrices are designed to accomplish other
functions through the combination of different format
features and materials.[15] A good example of this is the use
of drug delivery devices that can act simultaneously as
scaffolds for cells growth. Other approaches include, for
example, the combination (or incorporation) of micro-
spheres or nanospheres (with encapsulated cells, growth
factors or other therapeutic agents) with a polymeric matrix.
This type of multifunctional devices can also be designed to
act as an injectable material, with the advantage of allowing
minimal invasive surgery procedures for their implantation
in the body.
Another important field of current research in tissue
engineering scaffolding is related to the development of
external-stimuli-responsive matrices,[37,38] i.e., matrices
that have in their composition and structure certain ele-
ments that allow them to respond to a particular specific
stimuli that can be produced by different mechanisms,
such as magnetic, electric, ultrasound, irradiation or other
effects. Other scaffolds are designed to respond to several
physiological stimuli like pH, temperature or enzymatic
concentrations changes, just to cite some examples. This
can enhance the ability of tissue engineering constructs to
resemble natural human tissues and therefore perform a
better functioning in vivo, but also in vitro if provided with
adequate culture conditions.
3. Cells for Tissue Engineering
A further important consideration for the most widely
studied tissue engineering approaches, which are based on
the seeding and extended in vitro culturing of cells within
the scaffold prior to implantation, is the cell source and the
ability to control cell proliferation and differentiation.
Primary cells derived from the patient’s own healthy tissues
(i.e., autogenic cells) could be the first obvious choice,
since this avoids many of the problems associated with
immune rejection of foreign tissues.[36,39] However these
cells are not, in most cases, readily available in sufficient
quantities for immediate use. By in vitro culture their
number may be increased, but to reach a cell population
necessary for a specific application may take from days to
weeks,[36,39] mainly depending on cell type. Primary cells
derived from normal donors of the same (i.e., allogeneic
cells) or different species (i.e., xenogeneic cells) are, at least
in concept, readily available in sufficient quantities due to
the number of potential donors and to cryopreservation
possibilities. However, in this case, rejection by the host’s
immune system and the possibility of diseases transmis-
sion, are serious risks to be considered,[36,39] The use of cell
lines can overcome some of these limitations, but these
immortalized cells exhibit some of the properties of neo-
plastically transformed cells. Therefore, cells lines can be
considered to be partially transformed cells with a predis-
position to become fully neoplastic cells capable of forming
tumors in the recipient.[36]
The recent identification of human embryonic stem
cells[40,41] – cells that can give rise to essentially all cell
types in the body, depending on the culturing conditions
– offers probably the most exciting alternative source of
cells for tissue engineering. However, researchers are still
far from being able to control the differentiation of em-
bryonic stem cells in culture. In addition, the research on
embryonic cells brings up a range ethical and legislative
problems[40,41] that differ from country to country. A more
immediate goal would be to isolate the so-called progenitor
cells from tissues. These are stem cells that have already
partly differentiated so as to change the course of their
development. However, because they are not yet fully
differentiated, they stay flexible enough to give origin to
several different cell types.[40,41] For example, from the
human bone marrow or from adipose tissue it is possible to
isolate progenitor cells that can be differentiated in the
laboratory to form osteoblasts that make bone.[42] These
recent developments in the stem cell field have impacted
significantly on the progress of tissue engineering,[42] and
have opened a novel avenue for obtaining an unlimited
supply of cells.
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4. Cell Culturing in Tissue Engineering:
Static Conditions and Bioreactors
Besides the selection of the scaffold material and the cell
source (the two main components of tissue engineering
approaches based on in vitro culturing of cells-scaffold
constructs), it is necessary to develop more advanced
procedures for growing cells in large quantities,[43,44] opti-
mizing the in vitro culturing systems currently used. The
most widely used culturing technique in tissue engineering
studies is static culturing, which is often characterized by
non-homogenous cell distribution, confining the majority
of the cells to the outer surfaces of the scaffold, which in
turn results to an inhomogeneous distribution of the in vitro
generated extracellular matrix.[45–47] In order to overcome
this limitation, several culturing systems which consist
basically on using growth chambers equipped with stirrers
and sensors that regulate the appropriate amounts of
nutrients, gases and waste products have been develop-
ed.[45–47] These systems, so-called bioreactors, may have
different designs, attempting to achieve one or more of the
following objectives: i) maintain an uniform distribution of
cells into the 3D scaffolds, ii) provide adequate levels of
oxygen, nutrients, cytokines and growth factors iii) expose
the cultured cells to mechanical stimuli. Furthermore,
experiments involving in vitro bioreactor culturing can also
be designed to study the effects of specific biochemical and
physical signal involved in cell/tissue development and
function, providing useful information on the processes that
lead to the formation of 3-D tissues starting from cells/
scaffolds tissue engineered constructs.[45] Bioreactors are
also one of the focus of the development of a manufacturing
technology for tissue engineered products that can be used
‘‘in the real industrial world’’, because they represent a
chemically and mechanically controlled environment in
which a tissue-like construct can be grown in reproducible
conditions.[43]
5. In Vivo Functionality: Animal Models
Following in vitro studies and prior to clinical trials it is
current and logical to perform in vivo studies in different
animal models.[48–50] Several parameters are in the centre
of such evaluation. Inflammatory response for example, is
crucial and has to be evaluated for any type of biomaterial
since an unresolved inflammatory process will ultimately
will lead to rejection. It is however, of major importance to
reduce as much as possible the number of animals involved
in the in vivo evaluation of potential biomaterials and/or
tissue engineering scaffolds and constructs.
In our group we believe in an approach that tries to study
exhaustively the developed constructs in vitro minimizing
the number of animal testing. This is also the approach of
the European Union (EU) Network of Excellence on Tissue
Engineering of Bone and Cartilage that we coordinate
(EXPERTISSUES) and involves 20 partners from 13 coun-
tries.[51] However before any clinical application of tissue
engineering constructs (so called combination products)
animal experimentation is always required. For achieving
this goal it is crucial to establish strict and standardized
protocols of implantation as well as adequate animal
models.[48,50] The models have to be optimized in order to
provide information in different areas avoiding then the use
of excessive animals. The use of implantation procedures
that can be compared with others used in different groups is
of main importance.
The first step of animal implantation studies that is
relevant for tissue engineering involves the implantation of
the developed scaffolds, on its own (without cells) or after
being seeded with cells, in a subcutaneous model (many
times nude mice in order to be able to use human cells).[52,53]
The subcutaneously implantation of the scaffolds is aimed
in the non-cell seeded materials to determine the effect of a
specific material degradation and resorption by products in
triggering the immune system and non-specific inflamma-
tory reactions. The implanted species are typically harvest-
ed after different times and histological analysis is
performed. Classical immunohistochemistry techniques
are then used to identify the type of cells at the interface
material-tissue and complemented with gene expression
analysis in situ (ELISA and RT-PCR) for quantification of
inflammatory chemical mediators also know to have a
major role in resorption processes. It is also possible to use
the in vivo experiments to apply in situ methods of patho-
logy to study the tissue reaction to implanted materials. The
same model can be used with scaffolds seeded with cells to
look for instances for the osteogenic potential of the
constructs in a non bony site local.[33,48]
Another type of approach aims to understand bioma-
terial-related functionality facilitating advances in the
construction of improved and novel scaffolds for tissue
engineering. Again subcutaneous implantation can be per-
formed. Properties such as porosity, pore size and
interconnectivity of the produced scaffolds are then
evaluated in terms of suitability to encourage tissue growth
and vascularization.[54–56] Furthermore, it is important the
degradation rate to be coupled to the rate of tissue
formation, which can also be evaluated in this type of
experiments.
More relevant experiments have to be performed in larger
animals, typically using critical size (calvarial, femoral,
etc.) defects.[57] Typically studies that start from rats and
mice proceed to rabbits and goats or pigs, although some
groups also use dog models. The size of the animal is
especially relevant to assess the effect of load on load-
bearing implantation sites. In such type of experiments the
developed systems (scaffolds plus cells) are implanted,
including empty defects and scaffolds without cells as
controls. At appropriate time points animals are sacrificed
and tissue formation is analyzed by different methodologies,
740 M. E. Gomes, R. L. Reis
Macromol. Biosci. 2004, 4, 737–742 www.mbs-journal.de  2004 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
namely using micro-CT, immunohistochemistry, and
quantitative methodologies.
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